source
- Abbott Beats Q2 Expectations with Strong Device and Diagnostic Sales, Raises Profit ForecastAbbott reported second‑quarter results that exceeded analysts' forecasts, easing concerns about potential impact of ACA subsidy cuts on medtech firms. Diagnostics revenue jumped 42% year‑over‑year…
- Dimerix acquires Mission's phase-2 ready AKI drug in $292 million dealDimerix announced it has acquired the acute kidney injury candidate MTX652 from Mission Therapeutics in a deal valued at up to $292 million, including a $5 million upfront payment. Mission had com…